Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

Boehringer launches integrated Hispanic diabetes campaign

Creative development overseen Miami-based agency Republica

- PMLiVE

Sarah Verhoeff joins the board at Pan

UK advertising agency promotes its associate director

- PMLiVE

Merck Serono puts faith in lung cancer candidate

Continues tecemotide development despite underwhelming phase III results

- PMLiVE

GSK’s Revolade cleared for use in hepatitis C therapy

Adds to drug’s existing thrombocytopenia indication

- PMLiVE

Bioclusters benefit from pharma shake-up

Sweeping job cuts at Europe’s largest drugmakers in recent years have spread gloom through the pharma sector, but the release of talent is helping to drive the development of bioclusters

- PMLiVE

Advance the way you work with your experts

Written by Jan Steele PhD, operations director, Lucid

Lucid Group Communications Limited

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Unravelling China’s healthcare sector

How will health reforms, the tightening of regulations and the emergence of a domestic drug industry impact global pharmaceutical companies?

- PMLiVE

Janssen expands its ‘mobile health manager’

Add family support option to adherence campaign

- PMLiVE

GSK’s Chinese sales hit by scandal, say analysts

Company estimated to have lost a third of its revenues

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links